Pacific Biosciences of California, Inc. (PACB)
Healthcare
- Fundamental
- 1
- Sentiment
- 2
- Technical
- 2
Do Nothing: fundamentalScore 1 (below the required floor of 3) and qualitativeScore 2 (below the required floor of 3) hard-block any bullish entry; the chart itself shows only a weak short-term pullback (price 2.125 below SMA20/EMA9/EMA21, MACD histogram -0.05, ADX fading) with no confirmed reversal, and neither a pullback limit (which would face a 1.0xATR stop floor at 13.6% ATR) nor a breakout stop (no settled resistance within ~1 ATR overhead) qualifies.
Company overview
Pacific Biosciences of California, Inc. develops and manufactures genetic sequencing platforms, including the PacBio Sequencing Systems and SMRT cells. The company serves a global clientele across research, healthcare, and commercial sectors, with a strategic partnership with Invitae Corporation.
Fundamental
very weakPacific Biosciences exhibits speculative fundamentals with significant cash burn and reliance on external financing.
Speculative and balance-sheet constrained: revenue is broadly flat near $161M with a recovering mid-30s gross margin, but trailing operating cash burn of roughly $137M, negative shareholders' equity, $641M of deeply out-of-the-money convertibles, $318M of goodwill and a newly launched $100M at-the-market programme leave the equity dependent on external financing. Avoid.
Sentiment
weakSentiment is bearish due to a recent at-the-market equity program and management changes.
Near-term driver is a commenced $100M at-the-market equity program (2026-11-10, roughly 15% of market cap, regulator-confirmed via the issuer's 8-K) layered on a bearish-read CFO transition (2026-11-04) and a Q3 print the tape treated as neutral; the sentiment delta is determinate but flat (baseline polarity_score ≈ +0.07 vs scoring ≈ −0.00), so no improvement offsets the fresh supply overhang. Moderate red-flag cap applied — opportunistic dilutive offering, abrupt C-suite departure without permanent successor, and conflicting catalyst signals — and the rewarded-bullish test fails (no genuinely market-rewarded positive event in the window, only a single token sell-side price-target raise); Red-Flag Screen is severe-clean.
Technical
weakThe stock is experiencing a high-volatility pullback with no confirmed reversal.
Short-term structure is a rolling decline from the 2026-10-28 high (3.07) into today's 2.125 close, with price below every short-term average (SMA20 2.28, EMA9 2.32, EMA21 2.29, WMA9 2.31, WMA21 2.35, DEMA14 2.36) while still holding above SMA50 1.98 and SMA200 1.61 — a pullback within a longer-term uptrend that has not yet produced a reversal signal. RSI14 46.84 is neutral, Williams %R -85.91 is oversold, MACD line 0.08 is still above zero but sits below its signal (0.13) with histogram -0.05 widening negative, and ADX14 30.11 (direction-agnostic) is fading from 41.68 on 2026-10-29. ATR14 0.29 is 13.6% of price, so daily noise is very high. Score 2: mostly neutral-to-weak short-term tape, bounce-only; the longer-term trend is intact but momentum has rolled over.
You’re looking at 2026-11-11 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

